Post acquisition by Infinity, company was on a reset mode of sorts with average financial performance. Idle Cash was not adding much value given no additional plans were announced. The announcement of Yash Pharma acquisition which could be considered a small one but almost 20% of revenues is in real sense am inflection point business wise adding capabilities and distribution strength while company plans to further strengthen portfolio to other new segments as well
End of FY25 company would have enough cash to acquire another similar sized company. Current acquisition is @ 2x sales. More on this company post quarterly numbers.